E126: Risk Signals, JAKs, and SELECTIVE-ity
About this episode
Covering an interesting but ultimately disappointing post hoc study of multiple upadacitinib trials in RA. Initially some hope for clarity in the "Do JAKs cause all the badness?" questions, but ultimately landing me about where I have been since ORAL-SURVEILLANCE was published
Paper: https://www.sciencedirect.com/science/article/pii/S0003496724423091
Get every episode summarized
Each time The Evidence Based Rheumatology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Evidence Based Rheumatology Podcast
E133: Obinutuzumab for SLE (ALLEGORY)
The Evidence Based Rheumatology Podcast
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
The Evidence Based Rheumatology Podcast
E131: A Sham-Controlled Sham of a Trial: RESET-RA
The Evidence Based Rheumatology Podcast
E130: Telitacicept for SLE
The Evidence Based Rheumatology Podcast